Traders should monitor Eton's upcoming earnings calls for initial sales guidance and market uptake metrics for DESMODA. The product's success could significantly improve revenue visibility and justify a higher valuation multiple given the rare disease market and long patent life.
Price Chart
Executive Summary
Eton Pharmaceuticals received FDA approval for DESMODA (desmopressin acetate) Oral Solution, the first and only FDA-approved oral liquid formulation for the management of central diabetes insipidus in patients of all ages. The product is expected to launch on March 9, 2026, and could generate peak annual sales of $30-50 million, with patent protection extending through 2044.
Key Facts
- FDA approved DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus in all age groups
- DESMODA is the first and only FDA-approved oral liquid formulation of desmopressin
- Commercial launch expected March 9, 2026
- Product has potential peak annual sales of $30-50 million
- Patent protection extends through 2044
- Will be promoted by Eton's existing pediatric endocrinology sales team
- Available exclusively through Anovo specialty pharmacy with Eton Cares co-pay assistance program
Financial Impact
Potential peak annual sales of $30-50 million, representing a significant new revenue stream for Eton with long-term patent protection through 2044
Risk Factors
- Commercial execution risk in launching and gaining market adoption
- Potential competition from off-label use of existing formulations
- Reimbursement and payer coverage challenges despite co-pay assistance program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-005537 |
| Exhibit: ex_923604.htm | 0001437749-26-005537 |
| Document: 0001437749-26-005537-index-headers.html | 0001437749-26-005537 |
| Document: 0001437749-26-005537-index.html | 0001437749-26-005537 |
| Document: 0001437749-26-005537.txt | 0001437749-26-005537 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $51.16 (−3.25%) |
Oct 6, 2026 21d ago | 144 | $54.88 | awaiting T+60 | — | $51.16 (−6.78%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $51.16 (−13.55%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $51.16 (−15.34%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $51.16 (−15.35%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $51.16 (+18.86%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $51.16 (+16.79%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $51.16 (+11.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers